Prostate specific antigen values in prostate pathology. Isla de la Juventud. January 2013 to May 2014

Authors

  • David Rolando Pérez Cruz Hospital General Docente “Héroes del Baire”. Isla de la Juventud.
  • Madelyn Martínez Castro
  • José Moisés Águila Figueroa Hospital General Docente “Héroes del Baire”. Isla de la Juventud.

Keywords:

prostate specific antigen, prostatic hypertrophy, adenocarcinoma

Abstract

Prostate-specific antigen is especially important in evaluating the treatment of adenocarcinoma and is of interest to specify the behavior of its values ??in the Isle of Youth. With the objective of identifying the behavior of the values ??of the total and free PSA fractions in relation to prostate disease and the patient’s age, on the Isle of Youth in the period 2013 - 2014, a study was done descriptive, cross-sectional, based on the histopathological findings and PSA fractions, from 74 patients with prostate pathology, for the period specified. Hypertrophic prostate pathology was the most representative in the analyzed period (60.8%) followed by adenocarcinoma (21.6%); the most affected age group was between 70-74 years, accounting for 28.3%. the PSA values were variable in relation to the histopathological diagnosis. Serum PSA values ??behave interchangeably in adenocarcinoma and glandular hyperplasia

Downloads

Download data is not yet available.

Author Biographies

David Rolando Pérez Cruz, Hospital General Docente “Héroes del Baire”. Isla de la Juventud.

Especialista de 1er Grado en Laboratorio Clínico. Máster en Investigación de Aterosclerosis. Profesor Auxiliar

Madelyn Martínez Castro

Licenciada en Microbiología. Máster en Enfermedades Infecciosas. Prof. Asistente. Centro Municipal de Higiene y Epidemiología. Isla de la Juventud.

José Moisés Águila Figueroa, Hospital General Docente “Héroes del Baire”. Isla de la Juventud.

Especialista de 2do Grado de Anatomía patológica. Prof. Auxiliar.

References

Prestigiacomo AF, Stamey TA. Clinical usefulness of free and complexed PSA. Clin Lab Invest Suppl 2010; 221: 32-34.

T. Polascik, J. Oesterling, A. Partin. Prostate specific antigen: a decade of discovery-what we have learned, and where are we going. J Urol [revista en la Internet]. 1999; [citado 20 Marzo 2014] 162: 293-306. Disponible en: http://www. ncbi.nlm.nih.gov/pubmed/10411025

European Association of Urology. EAU Clinical Guidelines 2012 [Internet]. The Netherlands: EAU [citado el 22 de abril de 2012]. Disponible en: http://www.uroweb.org/guidelines/eau-clinical-guidelines/

Fernández M, Zarraonandía A, Krebs A, Díaz C, Domenech A, Figueroa A, et al. Programa continuo de detección precoz de cáncer de próstata: Análisis crítico a dos años de su implementación. Rev Chil Urol [revista en la Internet]. 2009 [citado 22 Marzo 2014]; 74(1):20-5. Disponible en: http://bases.bireme.br/cgi-bin/wxislind.exe/ iah/online/?IsisScript= iah/iah.xis&src=google&base=LILACS&lang=p&nextAction=lnk&exprSearch=562704&indexSearch=ID

Chen YT, Luderer AA, Thiel RP, Carlson G, Cuney CL, Soriano TF. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 2009; 47: 518-524.

Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med [revista en la Internet]. 2012 Jul 17 [citado 12 Febrero 2014]; 157 (2): 120-34. Disponible en: http://www.ncbi.nlm.nih. Gov / pubmed/ 22801674

Fowler JE Jr, Sanders J, Bigler SA, Rigdon J, Kilambi NK, Land SA. Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng./ml. J Urol [revista en la internet]. 2000 May [citado 12 Febrero 2014]; 163 (5):1467-70. Disponible en: http://www.ncbi.nlm.nih. gov/pubmed/ 10751859

Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, et al. Comparison of free psa, psa density, and age specific cutoffs for prostate cancer detection and staging. Urology [revista en la internet]. 2000 Aug 1 [citado 21 Noviembre 2013]; 56 (2): 255-60. Diponible en: http://www.ncbi.nlm.nih.gov/ pubmed/10925089

Thiel RP, Oesterling JE, Wojno KJ, Partin AW, Chan DW, Carter HB, et al. A multicenter comparison of the diagnostic performance of free prostate-specific antigen. Urology 2009; 48 (6A): 45- 50.

Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urology 2012; 151 (5): 1283-1290.

TecnoSuma Internacional (Página principal en Internet). [citado 18 de agosto 2013]. Disponible en: http://www.tecnosuma.com/productos.html.

Carter HB, Pearson JD, Metter EJ. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. Apr 22-29 1992; 267(16):2215-20.

Haythorn MR, Ablin RJ. Prostate-specific antigen testing across the spectrum of prostate cancer. Biomark Med. Aug 2011; 5 (4):515-26.

Chetner MP, Donnelly BJ, Hagen NA, Ross D, Ruether JD, et al. Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks). Can Urol Assoc J. Dec 2011; 5 (6):416-21.

Gorday W, Sadrzadeh H, de Koning L, Naugler C. Association of sociodemographic factors and prostate-specific antigen (PSA) testing. Clin Biochem. Aug 14 2014.

Ulmert D, Serio AM, O’Brien MF y cols. Longterm prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol. 2008; 26 (6): 823-4.

Martínez LR, Arias OA, Garlobo GG. Morbilidad en Consulta externa de urología. Rev Cubana Cir. 2002; 41: 1.

Martín JA; López, MA et al. Prostate adenomectomy in patients with high PSA. Rev. Arg. de Urol. Vol. 75 (4) 2010: 218-224.

Hu JC, Williams SB, Carter SC, Eggener SE, Prasad S, Chamie K, et al. Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. Urol Oncol. Jul 10 2014.

William GN, Ballentine HC, Theodore LD et al. Prostate cancer. Abeloff’s Clinical Oncology, fifth edition. Elsevier Inc. 2014; 84: 1463.

Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273 (4):289-94.

Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010; 10 (8):580-93.

Fang J, Metter EJ, Landis P, et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001; 58 (3):411-6.

Lilja H, Cronin AM, Dahlin A, et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011; 117 (6):1210-9.

Published

2014-07-10

How to Cite

1.
Pérez Cruz DR, Martínez Castro M, Águila Figueroa JM. Prostate specific antigen values in prostate pathology. Isla de la Juventud. January 2013 to May 2014. REMIJ [Internet]. 2014 Jul. 10 [cited 2024 Nov. 27];15(2). Available from: https://remij.sld.cu/index.php/remij/article/view/120

Issue

Section

Artí­culos originales